Pulmonary Cell News Volume 7.08 | Mar 1 2018

TOP STORY

New-Found Stem Cell Helps Regenerate Lung Tissue after Acute Injury

Researchers have identified a lung stem cell that repairs the organ’s gas exchange compartment, according to a new study. They isolated and characterized these progenitor cells from mouse and human lungs and demonstrated that they are essential to repairing lung tissue damaged by severe influenza and other respiratory ailments. [Press release from Perelman School of Medicine at the University of Pennsylvania discussing online prepublication in Nature] Press Release | Abstract

(Ranked by impact factor of the journal)

Global, Integrated Analysis of Methylomes and Transcriptomes from Laser Capture Microdissected Bronchial and Alveolar Cells in Human Lung

Scientists performed genome-wide bisulfite sequencing and RNA-seq from the same small groups of bronchial and alveolar cells isolated by laser capture microdissection from flash-frozen lung tissue of 12 donors and their peripheral blood T cells. [Epigenetics] Abstract

The Cytoprotective Role of DJ-1 and p45 NFE2 against Human Primary Alveolar Type II Cell Injury and Emphysema

Researchers isolated alveolar type II cells from control non-smokers, smokers and patients with emphysema to determine the role of nuclear factor, erythroid-derived 2 (NFE2). Low expression of p45 NFE2 in patients with emphysema correlated with a high extracellular matrix degradation. [Sci Rep] Full Article

Cystic Fibrosis Epithelial Cells Are Primed for Apoptosis as a Result of Increased Fas (CD95)

Investigators evaluated the relationship between dysfunctional cystic fibrosis transmembrane conductance regulator and apoptosis in cystic fibrosis (CF) airway epithelial cells. Apoptosis and associated caspase activity were analyzed in non-CF and CF tracheal and bronchial epithelial cell lines. [J Cyst Fibros] Abstract

Chronic β2AR Stimulation Limits CFTR Activation in Human Airway Epithelia

Researchers sought to understand the impact of chronic or excess β-agonist exposure on cystic fibrosis transmembrane conductance regulator (CFTR) activation in human airway epithelium. They demonstrated a greater than 60% reduction in both wild-type and modulator-corrected F508del-CFTR activation following chronic exposure to short- and long-acting β-agonists. [JCI Insight] Full Article

LUNG CANCER

SLC2A5 Promotes Lung Adenocarcinoma Cell Growth and Metastasis by Enhancing Fructose Utilization

Depletion of SLC2A5 undermined cell proliferation and invasion meanwhile increased cell apoptosis. Overexpression of SLC2A5 enhances cell proliferation, migration, invasion, and tumorigenic. [Cell Death Discov] Full Article

Target Delivery of Doxorubicin Tethered with PVP Stabilized Gold Nanoparticles for Effective Treatment of Lung Cancer

The in vitro cytotoxic effect of polyvinylpyrrolidone gold nanoparticles (PVP-AuNPs), free doxorubicin (Dox) and Dox@PVP-AuNPs inhibited the proliferation of human lung cancer cells with IC₅₀ concentration. Compared with control cells, PVP-AuNPs and free Dox, Dox@PVP-AuNPs can increase ROS generation, sensitize mitochondrial membrane potential and induces both early and late apoptosis in lung cancer cells. [Sci Rep] Full Article

Elevated RTP801 Promotes Cell Proliferation in Non-Small Cell Lung Cancer

Investigators found that the expression of RTP801 significantly increased in non-small cell lung cancer (NSCLC) tissues compared with that in normal lung and the level of RTP801 in peripheral blood of NSCLC patients was higher than that of healthy persons. They also showed that knockdown of RTP801 induced by lentivirus encoded RTP801-shRNA markedly inhibited the proliferation of A549 and SW900 cells. [IUBMB Life] Abstract

Knockdown of End-Binding Protein 1 Induces Apoptosis in Radioresistant A549 Lung Cancer Cells via p38 Kinase-Dependent COX-2 Upregulation

Scientists observed that end-binding protein 1 (EB1) was highly expressed in lung tumor tissues compared with normal non-tumor tissues based on immunohistochemical analysis of lung cancer tissue samples obtained from human tissue microarrays. EB1 was also highly overexpressed in radioresistant lung and cervical cancer cells, which exhibited increased cell death after EB1 silencing. [Oncol Rep] Abstract

The Fibrogenic Actions of the Coagulant and Plasminogen Activation Systems in Pulmonary Fibrosis

The authors describe the mechanisms by which components of two systems primarily involved in fibrin homeostasis contribute to interstitial fibrosis, with a particular focus on idiopathic pulmonary fibrosis. [Int J Biochem Cell Biol] Abstract | Graphical Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase III Tedopi^® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients following Immune Checkpoint Inhibitor Treatment

OSE Immunotherapeutics announced that the first approvals to resume patient accrual in the global Tedopi^® Phase III trial have been granted in the United States by the Institutional Review Boards. [OSE Immunotherapeutics] Press Release

Vertex Initiates Phase III Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation

Vertex Pharmaceuticals Incorporated announced that it is initiating a Phase III study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis who have two copies of the F508del mutation, the most common genetic form of the disease. [Vertex Pharmaceuticals Incorporated] Press Release

Daiichi Sankyo Initiates Phase I Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Cancer

Daiichi Sankyo Company Limited announced the first patient has been dosed in a Phase I study assessing the safety and tolerability of DS-1062, an investigational TROP2-targeting antibody drug conjugate, in patients with unresectable advanced non-small cell lung cancer who are refractory to or have relapsed following standard treatment or for whom no standard treatment is available. [Daiichi Sankyo Company Limited] Press Release

MabVax Therapeutics Reports Positive Safety Results from Initial Cohort of MVT-1075 Radioimmunotherapy Phase I Trial for the Treatment of Pancreatic, Colon and Lung Cancers

MabVax Therapeutics Holdings, Inc. announced positive interim results from the initial cohort of the Phase I clinical trial evaluating the company’s new human antibody-based radioimmunotherapy product MVT-1075 for the treatment of pancreatic, colon and lung cancer. [MabVax Therapeutics Holdings, Inc.] Press Release

BioAtla Announces First Patient Treated In PhaseI/II BA3011-001 Clinical Trial For CAB-AXL-ADC Therapeutic

BioAtla, LLC announced the treatment of the first patient in its clinical trial BA3011-001 for BioAtla’s BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC). [BioAtla^® LLC (PR Newswire Association LLC)] Press Release

EU Research Chief’s Next Act: Changing the Future of Academic Publishing

Robert-Jan Smits, one of Europe’s most powerful figures in research, has been appointed as a special envoy on open science at the European Commission, to help push efforts to make all publicly funded research in Europe freely available by 2020. [Science|Business] Editorial

Indian Scientist’s Sacking Spotlights Sexual Harassment

Female scientists in India hope that more academics will report sexual harassment without fear of jeopardizing their career or reputation, after a prominent biologist was sacked for allegedly harassing a staff member. [Nature News] Editorial

Here’s How the Scientists Running for Office Are Doing

They’re trained problem-solvers, but they have to learn to move beyond data to run successful campaigns. [The Atlantic] Editorial

Canadian Science Wins Billions in New Budget

Canadian Prime Minister Justin Trudeau’s administration released its 2018 budget and scientists couldn’t be happier. It includes almost CAD 4 billion (USD 3.1 billion) in new funding for science over the next five years, a significant portion of which will go to the country’s three granting councils. [Nature News] Editorial

NEW Stem Cells in Disease Modeling and Drug Discovery (SCDMDD) 2018
June 17-18, 2018
Melbourne, Australia

NEW Gordon Research Conferences: Notch Signaling in Development, Regeneration and Disease
July 22-27, 2018
Lewiston, Maine, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Position – Immune Oncology (H. Lee Moffitt Cancer & Research Institute)

NEW Postdoctoral Scholar – Autoimmune Diseases Affecting the Lung (University of California – San Francisco)

Research Fellow – Ex Vivo Response to PD-1 Blockade (Dana-Farber Cancer Institute)

Assistant Professor – Pulmonary Physiology (University of California, Riverside)

Multiple Positions – Pulmonary (University of Alabama at Birmingham)

Professor – Lung Cancer (University of Cincinnati)

Director – In Vitro Pharmacology (AstraZeneca)

Postdoctoral Fellow – Respiratory Therapy Area (AstraZeneca)

Postdoctoral Fellow – Lung Cancer (Van Ande Research Institute)

Postdoctoral Position – Pulmonary Disease Pathogenesis (Columbia University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.